Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

Sage Therapeutics (SAGE) PT Lowered to $84 at RBC Capital Following Earnings

May 4, 2021 12:52 PM EDT

RBC Capital analyst Brian Abrahams lowered the price target on Sage Therapeutics (NASDAQ: SAGE) to $84.00 (from $89.00) while maintaining a Sector Perform rating following results.

The analyst commented, "This morning, SAGE reported 1Q21 earnings and guided for $1.7B in cash by end-'21, for a burn rate of... More

SAGE Therapeutics (SAGE) Tops Q1 EPS by 27c, Revenues Miss

May 4, 2021 7:16 AM EDT

SAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($1.64), $0.27 better than the analyst estimate of ($1.91). Revenue for the quarter came in at $1.58 million versus the consensus estimate of $2 million.

Sage started 2021 with significant advances across our depression, neurology and neuropsychiatry franchises,... More